Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 15/20 | 1.00 |
| ▸ | TGM2 | P21980 | 1/20 | 0.72 |
| ▸ | NT5E | P21589 | 1/20 | 0.65 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.65 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.62 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.62 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.62 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16113628 | 1.00 | KRAS (1.00) | KRASTGM2NT5EFUT5P2RY2 | |
| SCHEMBL16113020 | 1.00 | KRAS (1.00) | KRASTGM2NT5EFUT5P2RY2 | |
| SCHEMBL17539280 | 0.97 | KRAS (0.94) | KRASTGM2NT5EFUT5 | |
| SCHEMBL22268204 | 0.94 | KRAS (0.89) | KRASTGM2NT5EFUT5P2RY2 | |
| SCHEMBL17539263 | 0.93 | KRAS (0.88) | KRASTGM2NT5EFUT5P2RY2 | |
| SCHEMBL17532543 | 0.93 | KRAS (0.86) | KRASTGM2NT5EFUT5 | |
| SCHEMBL16112811 | 0.92 | KRAS (0.86) | KRASTGM2NT5EFUT5P2RY2 | |
| SCHEMBL16112808 | 0.92 | KRAS (0.86) | KRASTGM2NT5EFUT5P2RY2 | |
| SCHEMBL17539277 | 0.92 | KRAS (0.85) | KRASTGM2NT5EFUT5 | |
| SCHEMBL17539261 | 0.90 | KRAS (1.00) | KRASTGM2NT5EFUT5P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 385 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353912-A1 | COMPOSITIONS AND METHODS COMPRISING ANTIBODIES THAT BIND TO COVALENT PEPTIDE CONJUGATES | UNIV NEW YORK (US) | 2025-11-20 | — | — | US | claimed |
| WO-2025226775-A2 | COMPOSITIONS AND METHODS FOR BINDING TO COVALENT PEPTIDE CONJUGATES | NEW YORK UNIVERSITY (US) | 2025-10-30 | — | — | WO | claimed |
| EP-4543931-A2 | COMPOSITIONS AND METHODS COMPRISING ANTIBODIES THAT BIND TO COVALENT PEPTIDE CONJUGATES | New York University (US) | 2025-04-30 | — | — | EP | claimed |
| CN-119866347-A | Compositions and methods comprising antibodies conjugated to covalent peptide conjugates | 纽约大学 | 2025-04-22 | — | — | CN | claimed |
| US-20240327542-A1 | COMPOSITIONS AND METHODS COMPRISING ANTIBODIES THAT BIND TO COVALENT PEPTIDE CONJUGATES | NEW YORK UNIVERSITY | 2024-10-03 | — | — | US | claimed |
| WO-2024091511-A1 | HETEROCYCLIC TEAD INHIBITORS | LIGHT HORSE THERAPEUTICS, INC. (US) | 2024-05-02 | — | — | WO | claimed |
| WO-2023250391-A9 | COMPOSITIONS AND METHODS COMPRISING ANTIBODIES THAT BIND TO COVALENT PEPTIDE CONJUGATES | NEW YORK UNIVERSITY (US) | 2024-04-25 | — | — | WO | claimed |
| WO-2023250391-A2 | COMPOSITIONS AND METHODS COMPRISING ANTIBODIES THAT BIND TO COVALENT PEPTIDE CONJUGATES | NEW YORK UNIVERSITY (US) | 2023-12-28 | — | — | WO | claimed |
| CN-122080069-A | Phospholipid compounds and uses thereof | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122055153-A | EGFR inhibitors for treating EGFR exon 20 mutation positive lung cancer | 安塔列斯疗法股份有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20260130893-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| CN-122029161-A | Crystalline forms of PI3K inhibitors and uses thereof | 蝎子疗法股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20260125366-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4735453-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-10723753-B2 | Ras inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20160046661-A1 | RAS INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-02-18 | — | — | US | disclosed |
| US-20160046661-A1 | RAS INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-02-18 | — | — | US | disclosed |
| EP-2970360-A1 | RAS INHIBITORS AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014160200-A9 | RAS INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2014-11-27 | — | — | WO | disclosed |
| WO-2014160200-A1 | RAS INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046661-A1 | RAS INHIBITORS AND USES THEREOF | KRAS, NRAS, RASGRP1 | KRAS 1/4885TGM2 3081/4885NT5E 2879/4885 |
| US-20250353912-A1 | COMPOSITIONS AND METHODS COMPRISING ANTIBODIES THAT BIND TO COVALENT PEPTIDE CONJUGATES | MICA, CD74, HLA-DRB1 | KRAS 2277/4885TGM2 1657/4885NT5E 3012/4885 |
| US-20260130893-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | KRAS 186/4885TGM2 2813/4885NT5E 1962/4885 |
| US-10723753-B2 | Ras inhibitors and uses thereof | KRAS, NRAS, RASGRP1 | KRAS 1/4885TGM2 3081/4885NT5E 2879/4885 |
| US-20260125366-A1 | METHODS FOR TREATING CANCER | AKT2, AKT3, PIK3R5 | KRAS 132/4885TGM2 4436/4885NT5E 1276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.